A Multicenter, Randomized, Open-label, Phase II Trial Aiming to Evaluate the Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2 Positive Breast Cancer Patients
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2019
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary) ; Pegfilgrastim (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms BREASTIMMU02
- 21 Aug 2018 Planned End Date changed from 1 Oct 2021 to 1 Nov 2021.
- 30 Jul 2018 Status changed from not yet recruiting to recruiting.
- 04 Jul 2018 New trial record